Baird Financial Group
CPRX

Baird Financial Group’s Catalyst Pharmaceutical CPRX Stock Holding History

Baird Financial Group’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-29,511
Closed -$548K – 1698
2022
Q4 		$548K Buy
+29,511
New +$454K ﹤0.01% 1262

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $18.8B AUM 29.2% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Baird Financial Group's CPRX Position: Q1 2023 in Review

Baird Financial Group sold out of Catalyst Pharmaceutical (CPRX) in Q1 2023, closing a stake of 29,511 shares — an estimated $548K sold.

Baird Financial Group first reported a position in CPRX in Q4 2022 and held it in 1 quarter. The position peaked at $548K in Q4 2022. 259 funds tracked by Wall St. Rank hold CPRX as of Q1 2023.

  • Baird Financial Group reported no remaining Catalyst Pharmaceutical position as of Q1 2023 after selling out during the quarter.
  • Baird Financial Group sold 29,511 Catalyst Pharmaceutical shares in Q1 2023, an estimated $548K.
  • Baird Financial Group first reported a position in Catalyst Pharmaceutical in Q4 2022 and held it in 1 quarter.
  • Baird Financial Group's Catalyst Pharmaceutical position peaked at $548K in Q4 2022.
  • 259 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2023.

Based on Baird Financial Group's 13F filing for Q1 2023, filed 15 May 2023.